FORM 7
MONTHLY PROGRESS REPORT

Name of Listed Issuer: **Doseology Sciences Inc. (the "Issuer")**

Trading Symbol: **MOOD**

Number of Outstanding Listed Securities: **8,011,621 common shares**

Date: **March 31, 2026**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

(a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.

(b) The term "Issuer" includes the Issuer and any of its subsidiaries.

(c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issues was inactive disclose this fact.

See Item 2 below for a complete overview and discussion of the Issuer's activities for the month of March 2026.

2. Provide a general overview and discussion of the activities of management.

The Issuer continued to direct its efforts towards driving sales of its branded line of gummies and collagen products. The Issuer maintained its dedication to promoting its presence through established retail sales channels in both physical and online spaces. Additionally, the Issuer has been establishing the necessary infrastructure to support their market entry into the functional oral stimulant products.

On March 4, 2026, the Issuer announced the launch of the Feed That Brain® Energy Pouches, marking the Issuer's first direct-to-consumer pilot program in the United States.

Feed That Brain Energy Pouches deliver clean, controlled energy in a discreet oral pouch format, powered by Doseology®. The nicotine-free, caffeine-based product is designed to provide predictable, portion-controlled stimulation without sugar, smoke, or liquid consumption. The pouches are now available exclusively to U.S. consumers at feedthatbrain.com and Amazon.com.

The U.S. pilot represents a key milestone in the Issuer's strategy to validate oral pouch delivery as a scalable stimulant platform, beginning with non-nicotine energy products. The Issuer will use this phase to evaluate consumer adoption, usage frequency, and repeat purchase behaviour, with particular focus on underserved demographics seeking alternatives to traditional energy drinks.

Feed That Brain Energy Pouches are designed for modern, on-the-go use, offering consumers clarity and control without the volatility commonly associated with liquid energy formats. The product reflects Doseology's broader focus on precision dosing, predictability, and experience-led design.

The Issuer notes that increasing consumer adoption of oral pouch formats reflects a broader shift toward portable and discreet delivery systems. While Feed That Brain is nicotine-free, the rapid growth of the U.S. nicotine pouch category highlights rising acceptance of pouch-based delivery, supporting the long-term relevance of the format.

On March 4, 2026, the Issuer also granted 140,000 restricted share units ("RSUs") and 210,000 performance share units ("PSUs") to a director of the Issuer. The RSUs vest in equal monthly increments over 36 months from the date of grant. The PSUs vest upon achievement of defined performance milestones, aligning compensation with long-term value creation.

On March 11, 2026, the Issuer announced that its common shares commenced trading on the OTCQB® Venture Market in the United States under the symbol DOSEF. The OTCQB is designed for developing and growth-stage public companies that meet higher transparency and governance standards. The OTCQB Venture Market provides investors with greater comfort because companies must maintain current financial reporting, management certification, and ongoing compliance standards.

The Issuer also announced that, further to its news release of August 27, 2025 that announced the closing of the acquisition of the "*Feed That Brain*" division operated by Joseph Mimran & Associates Inc. (the "Vendor"), it has issued an aggregate of 75,000 pre-funded warrants (the "Pre-Funded Warrants") to the Vendor, based upon a deemed price of $1.00 per Pre-funded Warrant. Additional issuances of $75,000 of Pre-Funded Warrants are due on the one (1) year and eighteen (18) month anniversaries of the closing the acquisition in accordance with the asset purchase and sale agreement executed between the parties. The Pre-Funded Warrants are subject to a four-month hold period in accordance with applicable securities laws, which will expire on July 11, 2026.

On March 30, 2026, the Issuer announced its intention to complete a non-brokered private placement of up to 3,225,806 units (each, a "Unit") at a price of $0.62 per Unit to raise aggregate gross proceeds of up to $2,000,000 (the "Offering"). Further details will be provided when the Issuer completes the Offering.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

   See Item 2.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

   None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

   None.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

   None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

See Item 2.

8. Describe the acquisition of new customers or loss of customers.

N/A.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

N/A.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. Provide details of any securities issued and options or warrants granted.

The Issuer granted 140,000 RSUs and 210,000 PSUs to a director on March 4, 2026.

The Issuer issued 75,000 Pre-Funded Warrants and 92,591 RSUs to the Vendor on March 10, 2026.

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

N/A.

17. Discuss any trends, which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

N/A.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: **March 31, 2026.**.

Tim Corkum
Name of Director or Senior Officer

"Tim Corkum"
Signature

President
Official Capacity

Issuer Details Name of Issuer **Doseology Sciences Inc.**	For Month End **March 2026**	Date of Report YY/MM/DD **26/03/31**
Issuer Address **Suite 305, 9–3151 Lakeshore Rd.**		
City/Province/Postal Code **Kelowna, BC, V1W 3S9**	Issuer Fax No. **N/A**	Issuer Telephone No. **825-800-0115**
Contact Name **Tim Corkum**	Contact Position **President**	Contact Telephone No. **825-800-0115**
Contact Email Address **hello@doseology.com**	Web Site Address **https://doseology.com/**	